Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of lumasiran, an investigational RNAi therapeutic targeting the hydroxyacid oxidase 1 (HAO1) mRNA “ encoding glycolate oxidase (GO) “ in development for the treatment of primary hyperoxaluria type 1 (PH1). If approved by the European Commission (EC), lumasiran will be marketed in Europe under the brand name OXLUMO„¢.
PH1 is an ultra-rare orphan disease characterized by excessive oxalate production, which can lead to end-stage renal disease (ESRD) and other systemic complications. PH1 affects approximately 3.5 to 4 individuals per million in Europe and the United States. Heterogeneity in disease manifestation often contributes to delays in diagnosis, with a median time to diagnosis of approximately six years. PH1 leads to progressive kidney damage, and patients with advanced kidney disease require intensive dialysis to help filter waste products from their blood until they are able and eligible to receive a dual or sequential liver/kidney transplant, an invasive procedure associated with a high risk of morbidity and mortality, and life-long immunosuppression.
This positive CHMP opinion recognizes the potential of OXLUMO to address the urgent unmet need that exists for patients of all ages impacted by primary hyperoxaluria type 1. Since there are no approved pharmacologic treatment options for PH1, we believe this is very encouraging news for those living with this ultra-rare, potentially life-threatening disease and for their families, said Brendan Martin, Acting Head of Europe, Canada, Middle East and Africa (CEMEA), Alnylam Pharmaceuticals.
People living with PH1 experience a progressive decline in kidney function due to the overproduction of oxalate, which can lead to end-stage renal disease. Current treatment approaches aim to delay progression to renal failure but do not prevent oxalate overproduction, said Pushkal Garg, M.D., Chief Medical Officer, Alnylam Pharmaceuticals. In clinical trials, OXLUMO has demonstrated clinically meaningful and sustained reductions in urinary and plasma oxalate, and an encouraging safety and tolerability profile. Were pleased that the CHMP has recognized the urgent need for new treatments across all age groups with inclusion of the ILLUMINATE-B results for the initial approval recommendation.
The positive opinion is based on efficacy and safety findings of OXLUMO in PH1 patients, including data from both the ILLUMINATE-A and ILLUMINATE-B Phase 3 studies. Key primary and secondary endpoints included the reduction of urinary and plasma oxalate, and the proportion of patients achieving normalization or near-normalization of urinary oxalate in response to OXLUMO relative to placebo. Findings from the ILLUMINATE-A pivotal study were presented in June 2020 at the virtual European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) International Congress. Topline results from the ILLUMINATE-B pediatric study were reported in September; results from the primary analysis will be presented at the upcoming virtual American Society of Nephrology (ASN) Annual Congress on October 22.
OXLUMO was granted Priority Medicines (PRIME) designation by the EMA as well as Orphan Designation in the European Union. OXLUMO was also granted an Accelerated Assessment by the EMA, which is awarded to medicines deemed to be of major public health interest and therapeutic innovation and is designed to bring new treatments to patients more quickly. Alnylam filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The FDA has granted a Priority Review for the NDA and has set an action date of December 3, 2020 under the Prescription Drug User Fee Act (PDUFA).
About OXLUMO„¢ (lumasiran)
OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) for the treatment of primary hyperoxaluria type 1 (PH1) in all age groups. HAO1 encodes glycolate oxidase (GO), an enzyme upstream of the disease-causing defect in PH1. OXLUMO works by degrading HAO1 messenger RNA and reducing the synthesis of GO, which inhibits hepatic production of oxalate “ the toxic metabolite responsible for the clinical manifestations of PH1. In the pivotal ILLUMINATE-A study, OXLUMO was shown to significantly reduce levels of urinary oxalate relative to placebo, with the majority of patients reaching normal or near-normal levels. Injection site reactions (ISRs) were the most common drug-related adverse reaction. In the ILLUMINATE-B pediatric Phase 3 study, OXLUMO demonstrated an efficacy and safety profile consistent to that observed in ILLUMINATE-A. OXLUMO utilizes Alnylams Enhanced Stabilization Chemistry (ESC)-GalNAc conjugate technology designed to increase potency and durability. OXLUMO is administered via subcutaneous injection once monthly for three months, then once quarterly at a dose based on actual body weight. For patients who weigh less than 10 kg, maintenance dosing remains monthly. OXLUMO should be administered by a healthcare professional. The safety and efficacy of OXLUMO are under evaluation by the FDA.
About ILLUMINATE-A Phase 3 Study
ILLUMINATE-A (NCT03681184) is a six-month randomized, double-blind, placebo-controlled, global, multicenter Phase 3 study (with a 54-month extension period) to evaluate the efficacy and safety of lumasiran in 39 patients, age six and older, with a documented diagnosis of PH1. Patients were randomized 2:1 to receive three monthly doses of lumasiran or placebo followed by quarterly maintenance doses at 3 mg/kg. The primary endpoint was the percent change in 24-hour urinary oxalate excretion from baseline to the average of months 3 to 6 in the patients treated with lumasiran as compared to placebo. Treatment arms were stratified at randomization based upon mean 24-hour urinary oxalate during screening (‰¤ 1.7 or > 1.7 mmol/24hr/1.73m2). Key secondary and exploratory endpoints were designed to evaluate additional measures of urinary oxalate, plasma oxalate, estimated glomerular filtration rate (eGFR), nephrocalcinosis, renal stone events, safety and tolerability.
About ILLUMINATE-B Phase 3 Study
ILLUMINATE-B (NCT03905694) is a six-month, single arm, open-label, multicenter Phase 3 trial (with a 54-month extension period) that enrolled 18 patients with PH1 under the age of six. Lumasiran was administered according to a weight-based dosing regimen. Patients below 10 kg of body weight received three monthly loading doses of lumasiran at 6 mg/kg followed by monthly maintenance doses at 3 mg/kg; patients at or above 10 kg but lower than 20 kg of body weight received three monthly loading doses at 6 mg/kg followed by quarterly maintenance doses; patients above the 20 kg body weight received three monthly loading doses at 3 mg/kg followed by quarterly maintenance doses. The primary efficacy endpoint of the study was the percent change from baseline to Month 6 in spot urinary oxalate:creatinine ratio averaged across Months 3 to 6. Key secondary and exploratory endpoints were designed to evaluate additional measures of urinary oxalate, plasma oxalate, estimated glomerular filtration rate (eGFR), nephrocalcinosis, renal stone events, safety, and tolerability.
About Primary Hyperoxaluria Type 1 (PH1)
PH1 is an ultra-rare disease in which excessive oxalate production results in the deposition of calcium oxalate crystals in the kidneys and urinary tract and can lead to the formation of painful and recurrent kidney stones and nephrocalcinosis. Renal damage is caused by a combination of tubular toxicity from oxalate, calcium oxalate deposition in the kidneys, and urinary obstruction by calcium oxalate stones. Compromised kidney function exacerbates the disease as the excess oxalate can no longer be effectively excreted, resulting in subsequent accumulation and crystallization in bones, eyes, skin, and heart, leading to severe illness and death. Current treatment options are very limited and include frequent renal dialysis or combined organ transplantation of liver and kidney, a procedure with high morbidity that is limited due to organ availability. Although a small minority of patients respond to vitamin B6 therapy, there are no approved pharmaceutical therapies for PH1.
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines, known as RNAi therapeutics, is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of todays medicines by potently silencing messenger RNA (mRNA) “ the genetic precursors “ that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylams commercial RNAi therapeutic products are ONPATTRO (patisiran), approved in the U.S., EU, Canada, Japan, Brazil, and Switzerland, and GIVLAARI (givosiran), approved in the U.S., Brazil and the EU. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam 2020” strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam is headquartered in Cambridge, MA.
Alnylam Forward Looking Statements
Various statements in this release concerning Alnylam’s future expectations, plans and prospects, including, without limitation, Alnylams views with respect to the safety and efficacy of lumasiran as demonstrated in the ILLUMINATE-A and ILLUMINATE-B Phase 3 studies and the potential for lumasiran to meet urgent unmet needs of PH1 patients across all age groups and have a favorable impact on PH1 disease manifestations, Alnylams expectations regarding the implications of the positive opinion recommending approval of lumasiran by the CHMP and the timeline for the potential approval of lumasiran by the EC following the positive CHMP opinion, [Alnylams expectations with respect to the review timeline for the lumasiran NDA by the FDA], Alnylams plans, assuming regulatory approvals, to bring lumasiran to patients with PH1 around the world, and expectations regarding the continued execution on its Alnylam 2020 guidance for the advancement and commercialization of RNAi therapeutics, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation: the direct or indirect impact of the COVID-19 global pandemic or any future pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays in diagnoses of rare diseases, initiation or continuation of treatment for diseases addressed by Alnylam products, or in patient enrollment in clinical trials, potential supply chain disruptions, and other potential impacts to Alnylams business, the effectiveness or timeliness of steps taken by Alnylam to mitigate the impact of the pandemic, and Alnylams ability to execute business continuity plans to address disruptions caused by the COVID-19 or any future pandemic; Alnylam’s ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for its product candidates, which may not be replicated or continue to occur in other subjects or in additional studies or otherwise support further development of product candidates for a specified indication or at all; actions or advice of regulatory agencies, which may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional pre-clinical and/or clinical testing; delays, interruptions or failures in the manufacture and supply of its product candidates, including lumasiran, or its marketed products; obtaining, maintaining and protecting intellectual property; intellectual property matters including potential patent litigation relating to its platform, products or product candidates; obtaining regulatory approval for its product candidates, including lumasiran, and maintaining regulatory approval and obtaining pricing and reimbursement for its products, including ONPATTRO and GIVLAARI; progress in continuing to establish a commercial and ex-United States infrastructure; successfully launching, marketing and selling its approved products globally, including ONPATTRO and GIVLAARI, and achieving net product revenues for ONPATTRO within its revised expected range during 2020; Alnylams ability to successfully expand the indication for ONPATTRO in the future; competition from others using technology similar to Alnylam’s and others developing products for similar uses; Alnylam’s ability to manage its growth and operating expenses within the ranges of guidance provided by Alnylam through the implementation of further discipline in operations to moderate spend and its ability to achieve a self-sustainable financial profile in the future without the need for future equity financing; Alnylams ability to establish and maintain strategic business alliances and new business initiatives; Alnylam’s dependence on third parties, including Regeneron, for development, manufacture and distribution of certain products, including eye and CNS products, Ironwood, for assistance with the education about and promotion of GIVLAARI, and Vir for the development of ALN-COV and other potential RNAi therapeutics targeting SARS-CoV-2 and host factors for SARS-CoV-2; the outcome of litigation; the risk of government investigations; and unexpected expenditures; as well as those risks more fully discussed in the “Risk Factors” filed with Alnylam’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings that Alnylam makes with the SEC. In addition, any forward-looking statements represent Alnylam’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.
Alnylam Pharmaceuticals, Inc.
(EU & Canada Head of Communications)
Christine Regan Lindenboom
(Investors and Media)
Transamerica Life Bermuda Solidifies its Capabilities with Key Senior Appointments
HONG KONG, Oct. 23, 2020 /PRNewswire/ — Transamerica Life (Bermuda) Ltd. (TLB) announced today that after nearly five years of successful leadership, Marc Lieberman, TLB’s CEO & President, will retire at the end of the year.
Under his stewardship, Mr. Lieberman has strengthened the company’s brand and today TLB is recognised as a leading provider of High Net Worth (HNW) life insurance solutions to customers in Asia and beyond – winning industry awards every year for the last four years. He also spearheaded the strategic direction and diversification of TLB’s product suite, from the successful launch of TLB’s innovative Wealthassure product to the significant enhancements of its flagship product, Universal Life Alpha. His foresight and determination has driven TLB’s digitalisation, operations, and services improvement, which has resulted in more capability building for the company.
TLB also announced that the company’s top leadership role will be separated into two jointly accountable and strategically aligned positions. Pending regulatory approval, Chirag Rathod, TLB’s current Chief Financial Officer, will take on the role of CEO, and Hazel Etherington, TLB’s current Chief Operations Officer, will assume the role of President effective 1 January 2021. Together they will form the Executive Committee of TLB, which will be chaired by the CEO.
The CEO leadership transition represents a significant milestone for TLB as it continues to pursue its aspirations to become the leading Asia-based HNW life insurance provider. Mr. Lieberman will remain to support the CEO transition until 31 December 2020.
Aegon, headquartered in The Hague, the Netherlands and parent of TLB, commented through Damiaan Jacobovits de Szeged, Chief Operating Officer, Aegon International, "We would like to pay special thanks to Marc for his exceptional leadership and many contributions towards growing TLB’s business over the years. We wish him all the best in his plans for retirement."
"We are delighted to appoint Chirag and Hazel to take over the top leadership positions at the company. Together we believe they are ideally positioned to steer TLB through the challenging market conditions and lead TLB into its next phase of long-term growth. Both are seasoned, skilled executives and together they bring nearly 50 years of industry experience to the table. They are well respected within the company and among industry peers. We are confident they will be successful in driving and creating long-term customer and shareholder value," he added.
TLB is a leading life insurance company dedicated to serving HNW and Ultra High Net Worth (UHNW) individuals. As the only pure HNW life insurance provider in Hong Kong, TLB has extensive experience in handling large sums assured and complex cases to support legacy and business planning for its customers.
About Transamerica Life (Bermuda) Ltd.: Transamerica Life (Bermuda) Ltd. (TLB) is a leading High Net Worth life insurance provider, dedicated to offering life protection to High Net Worth individuals, families and businesses across Asia and beyond. Transamerica has been in Asia for over 80 years and has been the pioneer in managing universal life portfolios since 1981. TLB was awarded International Life Insurer of the Year Award (Hong Kong) at the Asian Banking & Finance Insurance Asia Awards 2019. TLB is part of the Aegon Group, a leading, international financial services group providing life insurance, pensions and asset management based in The Hague, Netherlands. Further information about TLB is available here: www.transamericalifebermuda.com
About Aegon: Aegon’s roots go back 175 years – to the first half of the nineteenth century. Since then, Aegon has grown into an international company, with businesses in more than 20 countries in the Americas, Europe and Asia. Today, Aegon is one of the world’s leading financial services organisations, providing life insurance, pensions and asset management. Aegon’s purpose is to help people achieve a lifetime of financial security. Further information about Aegon is available here: www.aegon.com.
Related Links :
HKEX Welcomes First Hong Kong/Mainland ETF Cross-Listing
- First listings of ETFs in Hong Kong and Shenzhen under a new ETF Cross-listing Scheme
- Signing of MOU between HKEX and SZSE to promote the Scheme
- Hong Kong-listed ETF AUM grew to over HK$300 billion, as at 30 September 2020
HONG KONG, Oct. 23, 2020 /PRNewswire/ — Hong Kong Exchanges and Clearing Limited (HKEX) is pleased to welcome today (Friday) the first listings of Exchange Traded Funds (ETFs) in Hong Kong and Shenzhen under the Hong Kong-Mainland ETF Cross-listing Scheme, which facilitates cross-listing of ETFs between markets in Hong Kong and Mainland China.
HKEX Chief Executive Charles Li said: "The ETFs listed today, two each at HKEX and the Shenzhen Stock Exchange (SZSE) under the ETF Cross-listing Scheme, mark the exciting next chapter in cross-border ETFs. The Scheme facilitates access to new but established pools of liquidity and offers broader investment opportunities in both markets."
"This development is the result of our ongoing commitment to make Hong Kong Asia’s leading ETF marketplace, and represents an important step forward in our continued work with the onshore Chinese exchanges, and our regulators, to deliver a successful ETF Connect."
The two new ETFs listed today in Hong Kong – CSOP Yinhua CSI 5G Communications Theme ETF (Stock code: 3193) and Hang Seng Harvest CSI 300 Index ETF (Stock code: 3130 / 83130), have been approved by the Securities and Futures Commission. Through the Renminbi Qualified Foreign Institutional Investor (RQFII) status, each invests 90 per cent or more of its total net asset value in an ETF approved by the China Securities Regulatory Commission and currently listed on the SZSE.
HKEX and SZSE today also signed a memorandum of understanding (MOU) to promote the ETF Cross-listing Scheme and celebrate the well-established financial connections of the two markets.
Mr Li said: "Capital markets in Hong Kong and the Mainland have remained robust and resilient through recent challenging times, and today we are celebrating our shared strengths. The signing of the MOU is an important step forward in building valuable financial connections within the Greater Bay Area."
Since the first ETF listed on HKEX in 1999, Hong Kong’s Exchange Traded Products (ETPs) market, which include ETFs and Leveraged and Inverse Products, has developed into one of the most diverse product markets in Asia. With over 130 ETFs listed on HKEX, Hong Kong-listed ETFs trade over HK$6.7 billion a day (up from an average daily turnover of HK$4.5 billion in 2018), with assets under management standing at over HK$300 billion as at 30 September 2020.
Further information about Hong Kong-listed ETPs is available in HKEX’s website.
 For the first nine months in 2020.
Hong Kong Exchanges and Clearing Limited (HKEX) is one of the world’s major exchange groups, and operates a range of equity, commodity, fixed income and currency markets. HKEX is the world’s leading IPO market and as Hong Kong’s only securities and derivatives exchange and sole operator of its clearing houses, it is uniquely placed to offer regional and international investors access to Asia’s most vibrant markets.
HKEX is also the global leader in metals trading, through its wholly owned subsidiaries, The London Metal Exchange (LME) and LME Clear Limited. This commodity franchise was further enhanced with the launch of Qianhai Mercantile Exchange (QME), in China, in 2018.
HKEX launched the pioneering Shanghai-Hong Kong Stock Connect programme in 2014, further expanded with the launch of Shenzhen Connect in 2016, and the launch of Bond Connect in 2017.
Related Links :
VoIP Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024
The VoIP market will register an incremental spend of about USD 80 billion, growing at a CAGR of 10.40% during the five-year forecast period. A targeted strategic approach to VoIP sourcing can unlock several opportunities for buyers. This report also offers market impact and new opportunities created due to the COVID-19 pandemic. Download free sample pages
Key benefits to buy this report:
- What are the market dynamics?
- What are the key market trends?
- What are the category growth drivers?
- What are the constraints on category growth?
- Who are the suppliers in this market?
- What are the demand-supply shifts?
- What are the major category requirements?
- What are the procurement best practices in this market?
Information on Latest Trends and Supply Chain Market Information Knowledge centre on COVID-19 impact assessment
SpendEdge’s reports now include an in-depth complimentary analysis of the COVID-19 impact on procurement and the latest market data to help your company overcome sourcing challenges. Our VoIP market procurement intelligence report offers actionable procurement intelligence insights, sourcing strategies, and action plans to mitigate risks arising out of the current pandemic situation. The insights offered by our reports will help procurement professionals streamline supply chain operations and gain insights into the best procurement practices to mitigate losses.
Insights into buyer strategies and tactical negotiation levers:
Several strategic and tactical negotiation levers are explained in the report to help buyers achieve the best prices for VoIP market. The report also aids buyers with relevant VoIP pricing levels, pros and cons of prevalent pricing models such as volume-based pricing, spot pricing, and cost-plus pricing and category management strategies and best practices to fulfil their category objectives.
For more insights on buyer strategies and tactical negotiation levers Click Here
To access the definite purchasing guide on the voip that answers all your key questions on price trends and analysis:
- Am I paying/getting the right prices? Is my VoIP TCO (total cost of ownership) favorable?
- How is the price forecast expected to change? What is driving the current and future price changes?
- Which pricing models offer the most rewarding opportunities?
To get instant access to over 1000 market-ready procurement intelligence reports without any additional costs or commitment, Subscribe Now for Free.
Some of the top voip suppliers listed in this report:
This voip procurement intelligence report has enlisted the top suppliers and their cost structures, SLA terms, best selection criteria, and negotiation strategies.
- 8×8 Inc.
- AT&T Inc.
- Cisco Systems Inc.
- LogMeIn Inc.
- Mitel Networks Corp.
- Nextiva Inc.
- Ooma Inc.
- RingCentral Inc.
- Verizon Communications Inc.
- Vonage Holdings Corp.
This procurement report helps buyers identify and shortlist the most suitable suppliers for their voip requirements by answering the following questions:
- Am I engaging with the right suppliers?
- Which KPIs should I use to evaluate my incumbent suppliers?
- Which supplier selection criteria are relevant for?
- What are the voip category essentials in terms of SLAs and RFx?
Get access to regular sourcing and procurement insights to our digital procurement platform – Contact Us.
Table of Content
Category Pricing Insights
Category Management Strategy
Category Management Enablers
Suppliers under Coverage
US Market Insights
SpendEdge shares your passion for driving sourcing and procurement excellence. We are the preferred procurement market intelligence partner for 120+ Fortune 500 firms and other leading companies across numerous industries. Our strength lies in delivering robust, real-time procurement market intelligence reports and solutions. To know more https://www.spendedge.com/request-for-demo
US: +1 630 984 7340
UK: +44 148 459 9299
HKEX Welcomes First Hong Kong/Mainland ETF Cross-Listing
First listings of ETFs in Hong Kong and Shenzhen under a new ETF Cross-listing Scheme Signing of MOU between HKEX...
Transamerica Life Bermuda Solidifies its Capabilities with Key Senior Appointments
HONG KONG, Oct. 23, 2020 /PRNewswire/ — Transamerica Life (Bermuda) Ltd. (TLB) announced today that after nearly five years of...
Solar Panel Recycling Market | Growth In Solar PV Panel Installation to Boost the Market Growth | Technavio
The global solar panel recycling market size is poised to grow by USD 238.30 million during 2020-2024, progressing at a...
VoIP Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024
The VoIP market will register an incremental spend of about USD 80 billion, growing at a CAGR of 10.40% during...
CAD Software Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024
The CAD Software market will register an incremental spend of about USD 4 billion, growing at a CAGR of 8.45%...
Genesprint Group and Infrawear Release Rapid COVID-19 Antigen (AG) Throat and Mouth Swab Test on EU Market
Genesprint Group Ltd, a Hong Kong based testing company founded by Paul Tam, Dr. Sherman Fung, Dr. Chi C. Wong,...
MYAH Wins Prestigious Silmo D’Or Award
Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community, announced today that...
ABB: Q3 2020 Results
Third quarter revenues in all business areas were still dampened due to the impact of COVID-19, although a strong recovery...
COVID-19 Impact and Recovery Analysis |Fuel Cards Market Procurement Intelligence Report Forecasts Spend Growth of over $ 167 billion
The Fuel Cards Market is poised to experience spend growth of more than USD 167 billion between 2020-2024 at a...
The Law Offices of Frank R. Cruz Announces Investigation of First American Financial Corporation (FAF) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of First American Financial Corporation (“First American Financial” or the...